<!DOCTYPE article PUBLIC "-//NLM//DTD Journal Archiving and Interchange DTD v2.3 20070202//EN" "archivearticle.dtd">
<article article-type="other"><?properties open_access?><!-- Original-type: cl--><front><journal-meta><journal-id journal-id-type="nlm-ta">Br J Cancer</journal-id><journal-title>British Journal of Cancer</journal-title><issn pub-type="ppub">0007-0920</issn><issn pub-type="epub">1532-1827</issn><publisher><publisher-name>Nature Publishing Group</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="pmid">15226770</article-id><article-id pub-id-type="pmc">2409850</article-id><article-id pub-id-type="pii">6601985</article-id><article-id pub-id-type="doi">10.1038/sj.bjc.6601985</article-id><article-categories><subj-group subj-group-type="heading"><subject>Clinical</subject></subj-group></article-categories><title-group><article-title>Phase II study of weekly oxaliplatin and 24-h infusion of high-dose 5-fluorouracil and folinic acid in the treatment of advanced gastric cancer</article-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>Chao</surname><given-names>Y</given-names></name><xref ref-type="aff" rid="aff1">1</xref></contrib><contrib contrib-type="author"><name><surname>Yeh</surname><given-names>K H</given-names></name><xref ref-type="aff" rid="aff2">2</xref><xref ref-type="aff" rid="aff3">3</xref></contrib><contrib contrib-type="author"><name><surname>Chang</surname><given-names>C J</given-names></name><xref ref-type="aff" rid="aff2">2</xref></contrib><contrib contrib-type="author"><name><surname>Chen</surname><given-names>L T</given-names></name><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="aff" rid="aff8">8</xref></contrib><contrib contrib-type="author"><name><surname>Chao</surname><given-names>T Y</given-names></name><xref ref-type="aff" rid="aff4">4</xref></contrib><contrib contrib-type="author"><name><surname>Wu</surname><given-names>M F</given-names></name><xref ref-type="aff" rid="aff5">5</xref></contrib><contrib contrib-type="author"><name><surname>Chang</surname><given-names>C S</given-names></name><xref ref-type="aff" rid="aff6">6</xref></contrib><contrib contrib-type="author"><name><surname>Chang</surname><given-names>J Y</given-names></name><xref ref-type="aff" rid="aff2">2</xref><xref ref-type="aff" rid="aff8">8</xref></contrib><contrib contrib-type="author"><name><surname>Chung</surname><given-names>C Y</given-names></name><xref ref-type="aff" rid="aff6">6</xref></contrib><contrib contrib-type="author"><name><surname>Kao</surname><given-names>W Y</given-names></name><xref ref-type="aff" rid="aff4">4</xref></contrib><contrib contrib-type="author"><name><surname>Hsieh</surname><given-names>R K</given-names></name><xref ref-type="aff" rid="aff7">7</xref></contrib><contrib contrib-type="author"><name><surname>Cheng</surname><given-names>A L</given-names></name><xref ref-type="aff" rid="aff2">2</xref><xref ref-type="corresp" rid="caf1">*</xref></contrib></contrib-group><aff id="aff1"><label>1</label><sup>1</sup>Taipei Veterans General Hospital, Taipei, Taiwan</aff><aff id="aff2"><label>2</label><sup>2</sup>National Taiwan University Hospital, Taipei, Taiwan</aff><aff id="aff3"><label>3</label><sup>3</sup>Far Eastern Memorial Hospital, Taipei, Taiwan</aff><aff id="aff4"><label>4</label><sup>4</sup>Tri-Service General Hospital, Taipei, Taiwan</aff><aff id="aff5"><label>5</label><sup>5</sup>Chung Shan Medical and Dental College Hospital, Taipei, Taiwan</aff><aff id="aff6"><label>6</label><sup>6</sup>Changhua Christian Hospital, Taipei, Taiwan</aff><aff id="aff7"><label>7</label><sup>7</sup>Mackay Memorial Hospital, Taipei, Taiwan</aff><aff id="aff8"><label>8</label><sup>8</sup>National Health Research Institutes, Taipei, Taiwan</aff><author-notes><corresp id="caf1"><label>*</label>Author for correspondence: <email xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="mailto:andrew@ha.mc.ntu.edu.tw">andrew@ha.mc.ntu.edu.tw</email></corresp></author-notes><pub-date pub-type="epub"><day>29</day><month>06</month><year>2004</year></pub-date><pub-date pub-type="collection"><day>27</day><month>07</month><year>2004</year></pub-date><pub-date pub-type="ppub"><day>02</day><month>08</month><year>2004</year></pub-date><volume>91</volume><issue>3</issue><fpage>453</fpage><lpage>458</lpage><history><date date-type="received"><day>07</day><month>01</month><year>2004</year></date><date date-type="rev-recd"><day>10</day><month>05</month><year>2004</year></date><date date-type="accepted"><day>13</day><month>05</month><year>2004</year></date></history><copyright-statement>Copyright 2004, Cancer Research UK</copyright-statement><copyright-year>2004</copyright-year><permissions><copyright-holder>Cancer Research UK</copyright-holder></permissions><kwd-group><kwd>oxaliplatin</kwd><kwd>high-dose 5-fluorouracil</kwd><kwd>folinic acid</kwd><kwd>advanced gastric cancer</kwd></kwd-group></article-meta></front><body><p>Gastric cancer is the second leading cause of cancer death worldwide (<xref ref-type="other" rid="bib18">Ho, 1988</xref>; <xref ref-type="other" rid="bib37">Roder, 2002</xref>). The prognosis is generally poor, with overall 5-year survival ranged from 5 to 15&#x00025;. Most patients present with advanced or metastatic diseases, for which curative resection is not possible. Chemotherapy is used primarily for palliation of symptoms (<xref ref-type="other" rid="bib17">Findlay and Cunningham, 1993</xref>; <xref ref-type="other" rid="bib45">Wils, 1996</xref>; <xref ref-type="other" rid="bib15">De Vivo <italic>et al</italic>, 2000</xref>). In the past three decades, a variety of chemotherapy regimens were developed for the treatment of advanced gastric cancer (<xref ref-type="other" rid="bib30">MacDonald <italic>et al</italic>, 1980</xref>; <xref ref-type="other" rid="bib36">Preusser <italic>et al</italic>, 1989</xref>; <xref ref-type="other" rid="bib44">Wilke <italic>et al</italic>, 1990</xref>; <xref ref-type="other" rid="bib46">Wils <italic>et al</italic>, 1991</xref>; <xref ref-type="other" rid="bib24">Kim <italic>et al</italic>, 1993</xref>; <xref ref-type="other" rid="bib13">Cocconi <italic>et al</italic>, 1994</xref>; <xref ref-type="other" rid="bib54">Zaniboni <italic>et al</italic>, 1995</xref>; <xref ref-type="other" rid="bib47">Ychou <italic>et al</italic>, 1996</xref>; <xref ref-type="other" rid="bib11">Cheng <italic>et al</italic>, 1998</xref>). All these regimens had variable degrees of success in phase II trials; however, results of the subsequent phase III trials often failed to confirm the relatively high response rates of earlier reports (<xref ref-type="other" rid="bib22">Kelsen <italic>et al</italic>, 1992</xref>; <xref ref-type="other" rid="bib24">Kim <italic>et al</italic>, 1993</xref>; <xref ref-type="other" rid="bib13">Cocconi <italic>et al</italic>, 1994</xref>; <xref ref-type="other" rid="bib43">Webb <italic>et al</italic>, 1997</xref>; <xref ref-type="other" rid="bib40">Vanhoefer <italic>et al</italic>, 2000</xref>). The survival benefit was limited with overall survival consistently below 10 months, and substantial treatment-related toxicities were observed in most regimens (<xref ref-type="other" rid="bib42">Waters <italic>et al</italic>, 1999</xref>; <xref ref-type="other" rid="bib2">Ajani <italic>et al</italic>, 2003</xref>; <xref ref-type="other" rid="bib34">Ohtsu <italic>et al</italic>, 2003</xref>). Further, second-line chemotherapy is hardly effective in most trials, indicating the rapid emergence of drug resistance of gastric cancer cells to currently available anticancer drugs (<xref ref-type="other" rid="bib17">Findlay and Cunningham, 1993</xref>; <xref ref-type="other" rid="bib45">Wils, 1996</xref>; <xref ref-type="other" rid="bib15">De Vivo <italic>et al</italic>, 2000</xref>). New treatments with better therapeutic index or novel agents with lesser cross-resistance are needed.</p><p>Oxaliplatin is a third-generation platinum compound that has a wide range of antitumour activities (<xref ref-type="other" rid="bib31">Machover <italic>et al</italic>, 1996</xref>; <xref ref-type="other" rid="bib33">Monnet <italic>et al</italic>, 1998</xref>; <xref ref-type="other" rid="bib14">de Gramont <italic>et al</italic>, 2000</xref>; <xref ref-type="other" rid="bib32">Misset <italic>et al</italic>, 2001</xref>). Compared with cisplatin, oxaliplatin appears to have a better safety profile; and the cross-resistance to cisplatin is minimal (<xref ref-type="other" rid="bib27">Kollmannsberger <italic>et al</italic>, 2002</xref>). Oxaliplatin has higher anticancer activity than cisplatin in some preclinical experiments (<xref ref-type="other" rid="bib16">Di Francesco <italic>et al</italic>, 2002</xref>). Synergism between oxaliplatin and 5-fluorouracil (5-FU) has been demonstrated <italic>in vitro</italic> (<xref ref-type="other" rid="bib35">Pendyala and Creaven, 1993</xref>; <xref ref-type="other" rid="bib20">Hsu <italic>et al</italic>, 2000</xref>), and <italic>in vivo</italic> (<xref ref-type="other" rid="bib4">Andre <italic>et al</italic>, 1999</xref>). Combination of oxaliplatin and 5-FU has proven effective as first- or second-line treatment for advanced colorectal cancer (<xref ref-type="other" rid="bib31">Machover <italic>et al</italic>, 1996</xref>; <xref ref-type="other" rid="bib14">de Gramont <italic>et al</italic>, 2000</xref>). Preliminary results of several recent studies have suggested that various combinations of oxaliplatin and 5-FU may be as effective in gastric cancer as in colorectal cancer.</p><p>We have previously demonstrated that weekly 24-h infusion of high-dose 5-FU and folinic acid (FA), the HDFL regimen originally described by <xref ref-type="other" rid="bib5">Ardalan <italic>et al</italic> (1991)</xref>, appears to be particularly useful in gastric cancer (<xref ref-type="other" rid="bib48">Yeh and Cheng, 1994</xref>; <xref ref-type="other" rid="bib19">Hsu <italic>et al</italic>, 1997</xref>; <xref ref-type="other" rid="bib50">Yeh and Cheng, 1998</xref>). We have also provided evidence that prolonged exposure of gastric cancer cells to low concentration 5-FU for 24&#x02009;h enhances the inhibition of thymidylate synthase, and thereby increases the cytotoxicity of 5-FU (<xref ref-type="other" rid="bib53">Yeh <italic>et al</italic>, 2000b</xref>). Further, HDFL regimen has repeatedly been demonstrated to cause minimal myelosuppression (<xref ref-type="other" rid="bib19">Hsu <italic>et al</italic>, 1997</xref>; <xref ref-type="other" rid="bib51">Yeh <italic>et al</italic>, 1997</xref>; <xref ref-type="other" rid="bib50">Yeh and Cheng, 1998</xref>) and is therefore one of the ideal components for combination chemotherapy with other cytotoxic agents against gastric cancer. The possible mechanism responsible for the very low myelotoxicity of HDFL has recently been reported (<xref ref-type="other" rid="bib52">Yeh <italic>et al</italic>, 2000a</xref>).</p><p>This study sought to investigate if combination of oxaliplatin and HDFL may be a regimen with better therapeutic index for patients with advanced gastric cancer.</p><sec sec-type="methods"><title>PATIENTS AND METHODS</title><sec><title>Patients</title><p>Eligibility criteria of the patients included (1) pathologically confirmed, locally advanced (nonresectable), recurrent or metastatic gastric cancer, (2) objectively measurable disease by imaging studies, (3) no prior chemotherapy except postoperative adjuvant chemotherapy that was received more than 12 months before entry into the study, (4) ECOG (Eastern Cooperative Oncology Group) performance status &#x02a7d;2, (5) age between 18 and 75 years, (6) adequate hepatic, renal, and bone marrow functions, and (7) serum triglyceride &#x0003e;70&#x02009;mg&#x02009;dl<sup>&#x02212;1</sup>. The low limit for serum triglyceride was set to avoid HDFL-related hyperammonaemic encephalopathy, which occurs in around 5&#x00025; of Taiwanese patients (<xref ref-type="other" rid="bib49">Yeh and Cheng, 1997</xref>).</p><p>Exclusion criteria included (1) pre-existing peripheral neuropathy, (2) pregnant, breastfeeding, or woman of child-bearing potential without adequate contraception, (3) concurrent or prior malignancy except curatively resected cervical carcinoma <italic>in situ</italic> or squamous cell carcinoma of skin, (4) central nervous system metastases, (5) active infection, and (6) concurrent treatments that interfered with study evaluation. This study was approved by the ethics committee of all participating institutes. Signed informed consent was obtained from all patients.</p></sec><sec><title>Study design</title><p>This is a prospective, multicentre, phase II clinical trial.</p></sec><sec><title>Chemotherapy protocol</title><p>On days 1 and 8 of each cycle of chemotherapy, oxaliplatin 65&#x02009;mg&#x02009;m<sup>&#x02212;2</sup> was given as a 2-h intravenous infusion, then followed by 5-FU 2600&#x02009;mg&#x02009;m<sup>&#x02212;2</sup> and FA 300&#x02009;mg&#x02009;m<sup>&#x02212;2</sup>, as a continuous 24-h intravenous infusion. Treatment was repeated every 21 days. Treatment was continued until disease progression or unacceptable toxicity developed. Patients with complete response received at least two more cycles of chemotherapy.</p></sec><sec><title>Dose modification</title><p>Subsequent cycle of chemotherapy was withheld if peripheral blood neutrophils &#x0003c;1500&#x02009;mm<sup>&#x02212;3</sup> or platelets &#x0003c;100&#x02009;000&#x02009;mm<sup>&#x02212;3</sup> was noted on the due day. If recovery of neutrophils and platelets took more than 3 weeks after the due day, the patient was removed from protocol treatment. 5-FU was decreased to 2000&#x02009;mg&#x02009;m<sup>&#x02212;2</sup> for subsequent cycles if grade 4 thrombocytopenia or neutropenia developed in the precedent cycle of chemotherapy. Dose of 5-FU was further reduced to 1600&#x02009;mg&#x02009;m<sup>&#x02212;2</sup> for subsequent cycles if grade 4 thrombocytopenia or neutropenia developed again after first level of dose reduction of 5-FU. Oxaliplatin was decreased to 50&#x02009;mg&#x02009;m<sup>&#x02212;2</sup> if grade 4 thrombocytopenia or neutropenia developed after two levels of 5-FU dose reduction. If grade 3&#x02013;4 nonhaematological toxicities or grade 2 hand&#x02013;foot syndrome developed, 5-FU was decreased to 2000&#x02009;mg&#x02009;m<sup>&#x02212;2</sup> for subsequent cycles. Dose of 5-FU was further decreased to 1600&#x02009;mg&#x02009;m<sup>&#x02212;2</sup> for subsequent cycles if grade 3&#x02013;4 nonhaematological toxicities or grade 2 hand&#x02013;foot syndrome recurred after first levels of dose reduction of 5-FU. Oxaliplatin was decreased to 50&#x02009;mg&#x02009;m<sup>&#x02212;2</sup> if grade 3&#x02013;4 nonhaematological toxicities or grade 2 hand&#x02013;foot syndrome developed again after two levels of 5-FU dose reduction. For grade 2&#x02013;3 neurotoxicities, oxaliplatin was omitted until recovery of the neurotoxicities to grade 1 or less; and the dose of oxaliplatin was decreased to 50&#x02009;mg&#x02009;m<sup>&#x02212;2</sup> for subsequent cycles. Oxaliplatin was discontinued if grade 2&#x02013;3 neurotoxicities lasted for more than 3 weeks.</p></sec><sec><title>Evaluation of efficacy and toxicities</title><p>Evaluations before chemotherapy included medical history taking, physical examination, complete blood count, blood chemistry, chest X-ray, computed tomography (CT) scan of abdomen, and gastroendoscopy. After starting protocol treatment, complete blood count was examined weekly and blood chemistry every 3 weeks. Patients' condition and treatment-related toxicities were evaluated weekly. Tumour size was measured by imaging studies every 6 weeks. Tumour response was evaluated according to the World Health Organization criteria. Toxicities were graded using the NCI-Common Toxicity Criteria (version 1).</p></sec><sec><title>Statistical methods</title><p>The Simon two-stage design was used. The response rates of interest were <italic>P</italic><sub>0</sub>&#x0003d;40&#x00025; and <italic>P</italic><sub>1</sub>&#x0003d;60&#x00025;. If there were more than 12 responses in 29 patients in the first stage, the study would continue to 54 patients in the second stage. If there were more than 27 responses in 54 patients in the second stage, this treatment would be acceptable with <italic>&#x003b1;</italic> of 0.05 and <italic>&#x003b2;</italic> of 0.10.</p><p>Time to progression was defined as the duration from the date of starting protocol treatment to the date of documented disease progression or death by any cause. The overall survival was defined as the duration from the date of starting protocol treatment to the date of death. Kaplan&#x02013;Meier method was used in all survival analyses.</p></sec></sec><sec><title>RESULTS</title><sec><title>Patients and treatment</title><p>Between January 2001 through January 2002, 55 patients were enrolled into the study. Major clinicopathologic features of the patients are listed in <xref rid="tbl1" ref-type="table">Table 1</xref>
 <table-wrap id="tbl1" position="float"><label>Table 1</label><caption><p content-type="table-title">Clinicopathologic features of the patients</p></caption><table frame="hsides" rules="groups" border="1" width="85%"><colgroup><col align="left"/><col align="left"/></colgroup><thead valign="bottom"><tr><th align="left" valign="top" charoff="50">&#x000a0;</th><th align="left" valign="top" charoff="50"><bold>Patient number (&#x00025;)</bold></th></tr></thead><tbody valign="top"><tr><td align="left" valign="top" charoff="50">Total patients</td><td align="left" valign="top" charoff="50">55</td></tr><tr><td align="left" valign="top" charoff="50">Sex: male&#x0002f;female</td><td align="left" valign="top" charoff="50">36&#x0002f;19</td></tr><tr><td align="left" valign="top" charoff="50">ECOG performance</td><td align="left" valign="top" charoff="50">&#x000a0;</td></tr><tr><td align="char" valign="top" char="." charoff="50">&#x02003;0</td><td align="char" valign="top" char="." charoff="50">9 (16.4)</td></tr><tr><td align="char" valign="top" char="." charoff="50">&#x02003;1</td><td align="char" valign="top" char="." charoff="50">39 (70.9)</td></tr><tr><td align="char" valign="top" char="." charoff="50">&#x02003;2</td><td align="char" valign="top" char="." charoff="50">7 (12.7)</td></tr><tr><td align="left" valign="top" charoff="50"><italic>Treatments for primary tumour</italic></td><td align="left" valign="top" charoff="50">&#x000a0;</td></tr><tr><td align="left" valign="top" charoff="50">&#x02003;No prior therapy</td><td align="char" valign="top" char="." charoff="50">31 (56.4)</td></tr><tr><td align="left" valign="top" charoff="50">&#x02003;Surgery only</td><td align="char" valign="top" char="." charoff="50">18 (32.7)</td></tr><tr><td align="left" valign="top" charoff="50">&#x02003;Surgery &#x0002b; adjuvant chemotherapy</td><td align="char" valign="top" char="." charoff="50">6 (10.9)</td></tr><tr><td align="left" valign="top" charoff="50"><italic>Disease status</italic></td><td align="left" valign="top" charoff="50">&#x000a0;</td></tr><tr><td align="left" valign="top" charoff="50">&#x02003;Locally advanced</td><td align="char" valign="top" char="." charoff="50">3 (5.5)</td></tr><tr><td align="left" valign="top" charoff="50">&#x02003;Recurrence&#x0002f;metastasis</td><td align="char" valign="top" char="." charoff="50">52 (94.6&#x00025;)</td></tr><tr><td align="left" valign="top" charoff="50"><italic>Disease sites</italic></td><td align="left" valign="top" charoff="50">&#x000a0;</td></tr><tr><td align="left" valign="top" charoff="50">&#x02003;Liver</td><td align="char" valign="top" char="." charoff="50">26 (47.3)</td></tr><tr><td align="left" valign="top" charoff="50">&#x02003;Lymph nodes</td><td align="char" valign="top" char="." charoff="50">28 (50.9)</td></tr><tr><td align="left" valign="top" charoff="50">&#x02003;Peritoneum</td><td align="char" valign="top" char="." charoff="50">15 (27.3)</td></tr><tr><td align="left" valign="top" charoff="50">&#x02003;Gastrointestinal tract</td><td align="char" valign="top" char="." charoff="50">9 (16.4)</td></tr><tr><td align="left" valign="top" charoff="50">&#x02003;Bone</td><td align="char" valign="top" char="." charoff="50">9 (16.4)</td></tr><tr><td align="left" valign="top" charoff="50">&#x02003;Lung</td><td align="char" valign="top" char="." charoff="50">5 (9.1)</td></tr><tr><td align="left" valign="top" charoff="50">&#x02003;Others</td><td align="char" valign="top" char="." charoff="50">11 (20)</td></tr></tbody></table></table-wrap>. The median age of the patients was 64 years (range: 22&#x02013;75). A total of 323 cycles (median: 6, range: 1&#x02013;17) of chemotherapy were given. Median relative dose intensity was 95&#x00025; (range: 67&#x02013;100&#x00025;) for oxaliplatin, 95&#x00025; (range: 48&#x02013;100&#x00025;) for 5-FU, and 95&#x00025; (range: 48&#x02013;100&#x00025;) for FA. As oxaliplatin has a cumulative toxicity, the median relative dose intensity of oxaliplatin was 100&#x00025; (range: 70&#x02013;100&#x00025;) at cycle 3 and 88&#x00025; (range: 67&#x02013;100&#x00025;) at cycle 6, respectively. In total, 75&#x00025; of the patients received more than 80&#x00025; of intended doses of oxaliplatin, 5-FU and FA.</p></sec><sec><title>Efficacy</title><p>Five patients were not evaluable for response: four failed to return to the clinic for tumour measurements and one later found to have nonmeasurable tumours. Of the 50 patients evaluable for tumour response, there were 28 patients with partial remission (PR), four patients with stable disease (SD), and 18 patients with progressive disease (PD). The total tumour response rate was 56&#x00025; (95&#x00025; CI: 41.8&#x02013;70.3&#x00025;). The median time to tumour response was 3 months (range: 2.2&#x02013;8.3 months). Five out of the six patients, who had previously received postoperative adjuvant chemotherapy which contains cisplatin and 5-FU, achieved PR. Two responders went on to receive curative surgical resection or radiotherapy for the residual tumours. Both patients were alive and tumour-free at 16 and 25 months after starting protocol chemotherapy, respectively.</p><p>Median follow-up time of the whole group of 55 patients was 24.0 months as cut-off date for analysis on 25 July 2003. The median time to progression was 5.2 months (95&#x00025; CI: 4.0&#x02013;7.0 months) (<xref ref-type="fig" rid="fig1">Figure 1</xref><fig id="fig1"><label>Figure 1</label><caption><p>Time to progression of the 55 patients.</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" mime-subtype="jpeg" xlink:href="91-6601985f1"/></fig>). The median overall survival was 10.0 months (95&#x00025; CI: 8.0&#x02013;13.3 months) (<xref ref-type="fig" rid="fig2">Figure 2</xref><fig id="fig2"><label>Figure 2</label><caption><p>Overall survival of the 55 patients.</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" mime-subtype="jpeg" xlink:href="91-6601985f2"/></fig>).</p></sec><sec><title>Toxicity</title><p>All 55 patients were evaluated for toxicities (<xref rid="tbl2" ref-type="table">Table 2</xref>
 <table-wrap id="tbl2" position="float"><label>Table 2</label><caption><p content-type="table-title">Toxicity of the oxaliplatin-HDFL regimen</p></caption><table frame="hsides" rules="groups" border="1" width="85%"><colgroup><col align="left"/><col align="left"/><col align="left"/><col align="left"/><col align="left"/></colgroup><thead valign="bottom"><tr><th align="left" valign="top" charoff="50">&#x000a0;</th><th colspan="2" align="center" valign="top" charoff="50"><bold>Patients (<italic>n</italic>&#x0003d;55)</bold><hr/></th><th colspan="2" align="center" valign="top" charoff="50"><bold>Cycles (<italic>n</italic>&#x0003d;323)</bold><hr/></th></tr><tr><th align="left" valign="top" charoff="50">&#x000a0;</th><th align="left" valign="top" charoff="50"><bold>Grade</bold><hr/></th><th align="left" valign="top" charoff="50"><bold>Grade</bold><hr/></th><th align="left" valign="top" charoff="50"><bold>Grade</bold><hr/></th><th align="left" valign="top" charoff="50"><bold>Grade</bold><hr/></th></tr><tr><th align="left" valign="top" charoff="50"><bold>Toxicity</bold></th><th align="left" valign="top" charoff="50"><bold>1&#x02013;2</bold></th><th align="left" valign="top" charoff="50"><bold>3&#x02013;4</bold></th><th align="left" valign="top" charoff="50"><bold>1&#x02013;2</bold></th><th align="left" valign="top" charoff="50"><bold>3&#x02013;4</bold></th></tr></thead><tbody valign="top"><tr><td align="left" valign="top" charoff="50"><italic>Haematological</italic></td><td align="left" valign="top" charoff="50">&#x000a0;</td><td align="left" valign="top" charoff="50">&#x000a0;</td><td align="left" valign="top" charoff="50">&#x000a0;</td><td align="left" valign="top" charoff="50">&#x000a0;</td></tr><tr><td align="left" valign="top" charoff="50">&#x02003;Neutropenia</td><td align="char" valign="top" char="." charoff="50">72.7<sup>a</sup></td><td align="char" valign="top" char="." charoff="50">21.8</td><td align="char" valign="top" char="." charoff="50">34.3<sup>b</sup></td><td align="char" valign="top" char="." charoff="50">7.1</td></tr><tr><td align="left" valign="top" charoff="50">&#x02003;Leukopenia</td><td align="char" valign="top" char="." charoff="50">58.1</td><td align="char" valign="top" char="." charoff="50">7.2</td><td align="char" valign="top" char="." charoff="50">21.0</td><td align="char" valign="top" char="." charoff="50">1.8</td></tr><tr><td align="left" valign="top" charoff="50">&#x02003;Thrombocytopenia</td><td align="char" valign="top" char="." charoff="50">60.0</td><td align="char" valign="top" char="." charoff="50">12.7</td><td align="char" valign="top" char="." charoff="50">24.5</td><td align="char" valign="top" char="." charoff="50">5.0</td></tr><tr><td align="left" valign="top" charoff="50">&#x02003;Febrile neutropenia</td><td align="char" valign="top" char="." charoff="50">1.8</td><td align="char" valign="top" char="." charoff="50">5.4</td><td align="char" valign="top" char="." charoff="50">0.3</td><td align="char" valign="top" char="." charoff="50">0.9</td></tr><tr><td align="left" valign="top" charoff="50">&#x02003;Anaemia</td><td align="char" valign="top" char="." charoff="50">61.8</td><td align="char" valign="top" char="." charoff="50">9.0</td><td align="char" valign="top" char="." charoff="50">34.7</td><td align="char" valign="top" char="." charoff="50">2.8</td></tr><tr><td align="left" valign="top" charoff="50"><italic>Gastrointestinal</italic></td><td align="left" valign="top" charoff="50">&#x000a0;</td><td align="left" valign="top" charoff="50">&#x000a0;</td><td align="left" valign="top" charoff="50">&#x000a0;</td><td align="left" valign="top" charoff="50">&#x000a0;</td></tr><tr><td align="left" valign="top" charoff="50">&#x02003;Nausea</td><td align="char" valign="top" char="." charoff="50">81.8</td><td align="char" valign="top" char="." charoff="50">10.9</td><td align="char" valign="top" char="." charoff="50">38.4</td><td align="char" valign="top" char="." charoff="50">2.5</td></tr><tr><td align="left" valign="top" charoff="50">&#x02003;Vomiting</td><td align="char" valign="top" char="." charoff="50">87.2</td><td align="char" valign="top" char="." charoff="50">12.7</td><td align="char" valign="top" char="." charoff="50">31.6</td><td align="char" valign="top" char="." charoff="50">2.2</td></tr><tr><td align="left" valign="top" charoff="50">&#x02003;Diarrhoea</td><td align="char" valign="top" char="." charoff="50">69.1</td><td align="char" valign="top" char="." charoff="50">12.7</td><td align="char" valign="top" char="." charoff="50">22.0</td><td align="char" valign="top" char="." charoff="50">2.4</td></tr><tr><td align="left" valign="top" charoff="50">&#x02003;Stomatitis</td><td align="char" valign="top" char="." charoff="50">50.9</td><td align="char" valign="top" char="." charoff="50">3.6</td><td align="char" valign="top" char="." charoff="50">13.3</td><td align="char" valign="top" char="." charoff="50">0.9</td></tr><tr><td align="left" valign="top" charoff="50">&#x02003;Anorexia</td><td align="char" valign="top" char="." charoff="50">70.9</td><td align="char" valign="top" char="." charoff="50">1.8</td><td align="char" valign="top" char="." charoff="50">36.5</td><td align="char" valign="top" char="." charoff="50">0.3</td></tr><tr><td align="left" valign="top" charoff="50">&#x02003;Weight loss</td><td align="char" valign="top" char="." charoff="50">9.1</td><td align="char" valign="top" char="." charoff="50">0</td><td align="char" valign="top" char="." charoff="50">1.85</td><td align="char" valign="top" char="." charoff="50">0</td></tr><tr><td align="left" valign="top" charoff="50"><italic>Neuropathic</italic></td><td align="char" valign="top" char="." charoff="50">72.7</td><td align="char" valign="top" char="." charoff="50">12.7</td><td align="char" valign="top" char="." charoff="50">46.8</td><td align="char" valign="top" char="." charoff="50">2.2</td></tr><tr><td align="left" valign="top" charoff="50"><italic>Others</italic></td><td align="left" valign="top" charoff="50">&#x000a0;</td><td align="left" valign="top" charoff="50">&#x000a0;</td><td align="left" valign="top" charoff="50">&#x000a0;</td><td align="left" valign="top" charoff="50">&#x000a0;</td></tr><tr><td align="left" valign="top" charoff="50">&#x02003;Cardiac</td><td align="char" valign="top" char="." charoff="50">0</td><td align="char" valign="top" char="." charoff="50">1.8</td><td align="char" valign="top" char="." charoff="50">0</td><td align="char" valign="top" char="." charoff="50">0.3</td></tr><tr><td align="left" valign="top" charoff="50">&#x02003;Fever</td><td align="char" valign="top" char="." charoff="50">27.3</td><td align="char" valign="top" char="." charoff="50">1.8</td><td align="char" valign="top" char="." charoff="50">7.1</td><td align="char" valign="top" char="." charoff="50">0.3</td></tr><tr><td align="left" valign="top" charoff="50">&#x02003;Infection without neutropenia</td><td align="char" valign="top" char="." charoff="50">16.4</td><td align="char" valign="top" char="." charoff="50">0</td><td align="char" valign="top" char="." charoff="50">4.3</td><td align="char" valign="top" char="." charoff="50">0</td></tr><tr><td align="left" valign="top" charoff="50">&#x02003;Alopecia</td><td align="char" valign="top" char="." charoff="50">21.8</td><td align="char" valign="top" char="." charoff="50">0</td><td align="char" valign="top" char="." charoff="50">16.4</td><td align="char" valign="top" char="." charoff="50">0</td></tr></tbody></table><table-wrap-foot><fn id="tbfnote1"><label>a</label><p>All numbers are percentage of the 55 patients.</p></fn><fn id="tbfnote2"><label>b</label><p>All numbers are percentage of the 323 cycles given.</p></fn></table-wrap-foot></table-wrap>). Nine patients (14.5&#x00025;) discontinued treatment because of treatment-related toxicity. Eight out of these nine patients discontinued treatment because of oxaliplatin-related neurotoxicity. The median dose of oxaliplatin received by these eight patients was 910&#x02009;mg&#x02009;m<sup>&#x02212;2</sup> (range: 715&#x02013;1170&#x02009;mg&#x02009;m<sup>&#x02212;2</sup>). Another patient discontinued treatment due to heart failure, which was considered unrelated to chemotherapy.</p></sec></sec><sec><title>DISCUSSION</title><p>The results of this phase II study indicated that weekly oxaliplatin and 24-h infusion of high-dose 5-FU and FA is an effective combination chemotherapy for advanced gastric cancer. The overall response rate of 56&#x00025; was within the range (30&#x02013;70&#x00025;) of previous major protocols such as FAMTX, ELF, EAP, ECF, and recent taxane-based (<xref ref-type="other" rid="bib8">Bokemeyer <italic>et al</italic>, 1997</xref>; <xref ref-type="other" rid="bib26">Kollmannsberger <italic>et al</italic>, 2000</xref>; <xref ref-type="other" rid="bib9">Cascinu <italic>et al</italic>, 2001</xref>) or irinotecan-based regimens (<xref ref-type="other" rid="bib7">Bleiberg, 1999</xref>; <xref ref-type="other" rid="bib1">Ajani <italic>et al</italic>, 2002</xref>; <xref ref-type="other" rid="bib38">Slater <italic>et al</italic>, 2002</xref>). Recently, three other studies, using different administrating schedules of oxaliplatin and 5-FU, have also demonstrated a good efficacy in gastric cancer (<xref ref-type="other" rid="bib28">Louvet <italic>et al</italic>, 2002</xref>; <xref ref-type="other" rid="bib23">Kim <italic>et al</italic>, 2003</xref>; <xref ref-type="other" rid="bib3">Al-Batran <italic>et al</italic>, 2004</xref>). These phase II studies showed a response rates of 43&#x02013;44.9&#x00025; (<xref ref-type="other" rid="bib28">Louvet <italic>et al</italic>, 2002</xref>; <xref ref-type="other" rid="bib3">Al-Batran <italic>et al</italic>, 2004</xref>) and 26&#x00025; (<xref ref-type="other" rid="bib23">Kim <italic>et al</italic>, 2003</xref>) in the first- and second-line treatment, respectively. Oxaliplatin appears to be a useful adjunct to systemic chemotherapy against advanced gastric cancer. Currently, a randomised multicentre study (REAL-2) is underway with a two by two factorial design to compare the efficacy of capecitabine with 5-FU, and oxaliplatin with cisplatin in the ECF regimen, for patients with advanced oesophagogastric cancer. The study aims to enroll 1000 patients with the primary end point being 1-year survival. The interim analysis of the REAL-2 study showed good antitumour activity in favour of oxaliplatin and capecitabine with a response rate of 52&#x00025; (95&#x00025; CI: 34.4&#x02013;68.1&#x00025;) in an EOX (epirubicin, oxaliplatin, capecitabine) regimen (<xref ref-type="other" rid="bib39">Sumpter <italic>et al</italic>, 2003</xref>).</p><p>In this study, 5-FU and FA was given by two weekly 24-h infusion (the HDFL regimen) every 3 weeks. The rationale of this scheduling for 5-FU was based on our previous observations which indicated that HDFL is in general a highly effective and very safe regimen for advanced gastric cancer (<xref ref-type="other" rid="bib19">Hsu <italic>et al</italic>, 1997</xref>; <xref ref-type="other" rid="bib50">Yeh and Cheng, 1998</xref>). The patients' compliance was excellent. To avoid calcite precipitation and catheter blockage (<xref ref-type="other" rid="bib5">Ardalan <italic>et al</italic>, 1991</xref>, <xref ref-type="other" rid="bib6">1995</xref>), we decreased the dose of FA from 500 to 300&#x02009;mg&#x02009;m<sup>&#x02212;2</sup>, mixed the high-dose 5-FU and FA in the same infusion bag, and administered via an ambulatory infusion pump (<xref ref-type="other" rid="bib48">Yeh and Cheng, 1994</xref>). This effective, nonmyelosuppressive, convenient outpatient-based administration of HDFL has been widely used at many institutions in Taiwan since 1994 (<xref ref-type="other" rid="bib48">Yeh and Cheng, 1994</xref>), instead of much more complicated administration of LV5FU2 regimen (de Gramont regimen) in FOLFOX combination (<xref ref-type="other" rid="bib14">de Gramont <italic>et al</italic>, 2000</xref>). A phase II study of high-dose 5-FU (2600&#x02009;mg&#x02009;m<sup>&#x02212;2</sup>) and FA (500&#x02009;mg&#x02009;m<sup>&#x02212;2</sup>), German AIO regimen, has also been reported as a salvage regimen in gastric cancer with partial remissions of 18&#x00025; and stable disease of 41&#x00025; (<xref ref-type="other" rid="bib41">Vanhoefer <italic>et al</italic>, 1994</xref>). The decreased dose of FA (300&#x02009;mg&#x02009;m<sup>&#x02212;2</sup>) in our HDFL compared to German AIO regimen may also decrease the toxicity of grade 3&#x0002f;4 diarrhoea (<xref ref-type="other" rid="bib25">Kohne <italic>et al</italic>, 2003</xref>). Further, results of our <italic>in vitro</italic> studies have implied that strict avoidance of bolus injection of 5-FU is the key to avoid myelosuppression (<xref ref-type="other" rid="bib52">Yeh <italic>et al</italic>, 2000a</xref>). Although the best protocol of 5-FU remains to be explored (<xref ref-type="other" rid="bib21">Johnson <italic>et al</italic>, 1991</xref>; <xref ref-type="other" rid="bib29">Louvet <italic>et al</italic>, 1991</xref>), both clinical and laboratory data indicate that HDFL is one of the ideal components for combination chemotherapy with other cytotoxic agents against gastric cancer.</p><p>In this study, five out of six patients who had received prior adjuvant chemotherapy which contains cisplatin and 5-FU responded to the current protocol. A similar observation has recently been reported by <xref ref-type="other" rid="bib23">Kim <italic>et al</italic> (2003)</xref>. It appears that oxaliplatin has no significant cross-resistance with cisplatin in gastric cancer. Therefore, it is intriguing to examine if oxaliplatin is effective in second-line chemotherapy for gastric cancer patients recurrent from cisplatin-containing regimens.</p><p>Although survival is not a reliable end point for evaluation of efficacy in phase II trials, the median overall survival of 10.0 months in this study compared favourably to ECF (8.7 months), FAMTX (6.1 months), FAMTX (6.7 months), ELF (7.2 months), FUP (7.2 months), and FOLFOX 6 (8.6 months) (<xref ref-type="other" rid="bib43">Webb <italic>et al</italic>, 1997</xref>; <xref ref-type="other" rid="bib40">Vanhoefer <italic>et al</italic>, 2000</xref>; <xref ref-type="other" rid="bib28">Louvet <italic>et al</italic>, 2002</xref>). It also compares favourably to prior studies conducted in our institutions on similar groups of patients (<xref ref-type="other" rid="bib19">Hsu <italic>et al</italic>, 1997</xref>; <xref ref-type="other" rid="bib11">Cheng <italic>et al</italic>, 1998</xref>; <xref ref-type="other" rid="bib12">Chi <italic>et al</italic>, 1998</xref>).</p><p>Except for the oxaliplatin-related neurotoxicity (<xref ref-type="other" rid="bib10">Cassidy and Misset, 2002</xref>), the current oxaliplatin-HDFL protocol is generally well tolerated. Neurotoxicity was also found to be the predominant dose-limiting toxicity in another oxaliplatin-containing regimen for gastric cancer (<xref ref-type="other" rid="bib28">Louvet <italic>et al</italic>, 2002</xref>). Other major toxicities, including neutropenia, thrombocytopenia, stomatitis, and diarrhoea, were of the same range of severity as other major regimens such as FAMTX, ECF, FUP, ELF, and FOLFOX6 (<xref ref-type="other" rid="bib43">Webb <italic>et al</italic>, 1997</xref>; <xref ref-type="other" rid="bib40">Vanhoefer <italic>et al</italic>, 2000</xref>; <xref ref-type="other" rid="bib28">Louvet <italic>et al</italic>, 2002</xref>). Owing to patients' selection in phase II studies, it may not be possible or relevant to compare the toxicity profiles of the present study with three other phase II studies, using different administrating schedules of oxaliplatin and 5-FU in gastric cancer (<xref ref-type="other" rid="bib28">Louvet <italic>et al</italic>, 2002</xref>; <xref ref-type="other" rid="bib23">Kim <italic>et al</italic>, 2003</xref>; <xref ref-type="other" rid="bib3">Al-Batran <italic>et al</italic>, 2004</xref>). However, the haematological toxicity of the present study is still favourable and well tolerated with grade 3&#x02013;4 neutropenia and febrile neutropenia of 7.1 and 0.9&#x00025;, respectively, in a total of 323 cycles given. Further, the absence of grade-2 alopecia in this study compared favourably to other regimens.</p><p>We conclude that combination of weekly oxaliplatin and weekly 24-h infusion of 5-FU and FA is an active regimen with acceptable toxicities for the treatment of advanced gastric cancer.</p></sec></body><back><ack><p>We thank Dr WK Chan, for critical review and comments of this paper. This study was supported by grants from National Health Research Institutes, Taiwan; and Sanofi-Synthelabo Research, France.</p></ack><ref-list><ref id="bib1"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Ajani</surname><given-names>JA</given-names></name><name><surname>Baker</surname><given-names>J</given-names></name><name><surname>Pisters</surname><given-names>PW</given-names></name><name><surname>Ho</surname><given-names>L</given-names></name><name><surname>Mansfield</surname><given-names>PF</given-names></name><name><surname>Feig</surname><given-names>BW</given-names></name><name><surname>Charnsangavej</surname><given-names>C</given-names></name></person-group><article-title>CPT-11 plus cisplatin in patients with advanced, untreated gastric or gastroesophageal junction carcinoma: results of a phase II study</article-title><source>Cancer</source><year>2002</year><volume>94</volume><fpage>641</fpage><lpage>646</lpage><!--PubMed citation query: 'Cancer||94|641||bib1|'--><pub-id pub-id-type="pmid">11857295</pub-id></citation></ref><ref id="bib2"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Ajani</surname><given-names>JA</given-names></name><name><surname>Van Custum</surname><given-names>E</given-names></name><name><surname>Moiseyenko</surname><given-names>V</given-names></name><name><surname>Tjulandin</surname><given-names>M</given-names></name><name><surname>Fodor</surname><given-names>M</given-names></name><name><surname>Majlis</surname><given-names>A</given-names></name><name><surname>Boni</surname><given-names>C</given-names></name><name><surname>Zuber</surname><given-names>E</given-names></name><name><surname>Blattmann</surname><given-names>A</given-names></name></person-group><article-title>Docetaxel (D), cisplatin, 5-fluorouracil compare to cisplatin (C) and 5-fluorouracil (F) for chemotherapy-naive patients with metastatic or locally recurrent, unresectable gastric carcinoma (MGC): interim results of a randomized phase III trial (V325)</article-title><source>Proc Am Soc Clin Oncol</source><year>2003</year><volume>22</volume><fpage>249</fpage>abstract 999<!--PubMed citation query: 'Proc Am Soc Clin Oncol||22|249||bib2|'--></citation></ref><ref id="bib3"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Al-Batran</surname><given-names>SE</given-names></name><name><surname>Atmaca</surname><given-names>A</given-names></name><name><surname>Hegewisch-Becker</surname><given-names>S</given-names></name><name><surname>Jaeger</surname><given-names>D</given-names></name><name><surname>Hahnfeld</surname><given-names>S</given-names></name><name><surname>Rummel</surname><given-names>MJ</given-names></name><name><surname>Seipelt</surname><given-names>G</given-names></name><name><surname>Rost</surname><given-names>A</given-names></name><name><surname>Orth</surname><given-names>J</given-names></name><name><surname>Knuth</surname><given-names>A</given-names></name><name><surname>Jaeger</surname><given-names>E</given-names></name></person-group><article-title>Phase II trial of biweekly infusional fluorouracil, folinic acid, and oxaliplatin in patients with advanced gastric cancer</article-title><source>J Clin Oncol</source><year>2004</year><volume>22</volume><fpage>658</fpage><lpage>663</lpage><!--PubMed citation query: 'J Clin Oncol||22|658||bib3|'--><pub-id pub-id-type="pmid">14966088</pub-id></citation></ref><ref id="bib4"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Andre</surname><given-names>T</given-names></name><name><surname>Bensmaine</surname><given-names>MA</given-names></name><name><surname>Louvet</surname><given-names>C</given-names></name><name><surname>Francois</surname><given-names>E</given-names></name><name><surname>Lucas</surname><given-names>V</given-names></name><name><surname>Desseigne</surname><given-names>F</given-names></name><name><surname>Beerblock</surname><given-names>K</given-names></name><name><surname>Bouche</surname><given-names>O</given-names></name><name><surname>Carola</surname><given-names>E</given-names></name><name><surname>Merrouche</surname><given-names>Y</given-names></name><name><surname>Morvan</surname><given-names>F</given-names></name><name><surname>Dupont-Andre</surname><given-names>G</given-names></name><name><surname>de Gramont</surname><given-names>A</given-names></name></person-group><article-title>Multicenter phase II study of bimonthly high-dose leucovorin, fluorouracil infusion, and oxaliplatin for metastatic colorectal cancer resistant to the same leucovorin and fluorouracil regimen</article-title><source>J Clin Oncol</source><year>1999</year><volume>17</volume><fpage>3560</fpage><lpage>3568</lpage><!--PubMed citation query: 'J Clin Oncol||17|3560||bib4|'--><pub-id pub-id-type="pmid">10550155</pub-id></citation></ref><ref id="bib5"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Ardalan</surname><given-names>B</given-names></name><name><surname>Chua</surname><given-names>L</given-names></name><name><surname>Tian</surname><given-names>EM</given-names></name><name><surname>Reddy</surname><given-names>R</given-names></name><name><surname>Sridhar</surname><given-names>K</given-names></name><name><surname>Benedetto</surname><given-names>P</given-names></name><name><surname>Richman</surname><given-names>S</given-names></name><name><surname>Legaspi</surname><given-names>A</given-names></name><name><surname>Waldman</surname><given-names>S</given-names></name><name><surname>Morrell</surname><given-names>L</given-names></name></person-group><article-title>A phase II study of weekly 24-hour infusion with high-dose fluorouracil with leucovorin in colorectal carcinoma</article-title><source>J Clin Oncol</source><year>1991</year><volume>9</volume><fpage>625</fpage><lpage>630</lpage><!--PubMed citation query: 'J Clin Oncol||9|625||bib5|'--><pub-id pub-id-type="pmid">2066758</pub-id></citation></ref><ref id="bib6"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Ardalan</surname><given-names>B</given-names></name><name><surname>Flores</surname><given-names>MR</given-names></name><name><surname>Leichman</surname><given-names>CG</given-names></name><name><surname>Fleming</surname><given-names>TR</given-names></name><name><surname>Muggia</surname><given-names>FM</given-names></name><name><surname>Tangen</surname><given-names>CM</given-names></name><name><surname>Doroshow</surname><given-names>JH</given-names></name><name><surname>Meyers</surname><given-names>FJ</given-names></name><name><surname>Holcombe</surname><given-names>RF</given-names></name><name><surname>Weiss</surname><given-names>GR</given-names></name><name><surname>Mangalik</surname><given-names>A</given-names></name></person-group><article-title>A new complication of chemotherapy administered via permanent indwelling central venous catheter</article-title><source>Cancer</source><year>1995</year><volume>75</volume><fpage>2165</fpage><lpage>2168</lpage><!--PubMed citation query: 'Cancer||75|2165||bib6|'--><pub-id pub-id-type="pmid">7697607</pub-id></citation></ref><ref id="bib7"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Bleiberg</surname><given-names>H</given-names></name></person-group><article-title>CPT-11 in gastrointestinal cancer</article-title><source>Eur J Cancer</source><year>1999</year><volume>35</volume><fpage>371</fpage><lpage>379</lpage><!--PubMed citation query: 'Eur J Cancer||35|371||bib7|'--><pub-id pub-id-type="pmid">10448285</pub-id></citation></ref><ref id="bib8"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Bokemeyer</surname><given-names>C</given-names></name><name><surname>Lampe</surname><given-names>CS</given-names></name><name><surname>Clemens</surname><given-names>MR</given-names></name><name><surname>Hartmann</surname><given-names>JT</given-names></name><name><surname>Quietzsch</surname><given-names>D</given-names></name><name><surname>Forkmann</surname><given-names>L</given-names></name><name><surname>Kollmannsberger</surname><given-names>C</given-names></name><name><surname>Kanz</surname><given-names>L</given-names></name></person-group><article-title>A phase II trial of paclitaxel and weekly 24&#x02009;h infusion of 5-fluorouracil&#x0002f;folinic acid in patients with advanced gastric cancer</article-title><source>Anticancer Drugs</source><year>1997</year><volume>8</volume><fpage>396</fpage><lpage>399</lpage><!--PubMed citation query: 'Anticancer Drugs||8|396||bib8|'--><pub-id pub-id-type="pmid">9180395</pub-id></citation></ref><ref id="bib9"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Cascinu</surname><given-names>S</given-names></name><name><surname>Graziano</surname><given-names>F</given-names></name><name><surname>Barni</surname><given-names>S</given-names></name><name><surname>Labianca</surname><given-names>R</given-names></name><name><surname>Comella</surname><given-names>G</given-names></name><name><surname>Casaretti</surname><given-names>R</given-names></name><name><surname>Frontini</surname><given-names>L</given-names></name><name><surname>Catalano</surname><given-names>V</given-names></name><name><surname>Baldelli</surname><given-names>AM</given-names></name><name><surname>Catalano</surname><given-names>G</given-names></name></person-group><article-title>A phase II study of sequential chemotherapy with docetaxel after the weekly PELF regimen in advanced gastric cancer. A report from the Italian group for the study of digestive tract cancer</article-title><source>Br J Cancer</source><year>2001</year><volume>84</volume><fpage>470</fpage><lpage>474</lpage><!--PubMed citation query: 'Br J Cancer||84|470||bib9|'--><pub-id pub-id-type="pmid">11207039</pub-id></citation></ref><ref id="bib10"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Cassidy</surname><given-names>J</given-names></name><name><surname>Misset</surname><given-names>JL</given-names></name></person-group><article-title>Oxaliplatin-related side effects: characteristics and management</article-title><source>Semin Oncol</source><year>2002</year><volume>29</volume><supplement>5 Suppl 15</supplement><fpage>11</fpage><lpage>20</lpage><!--PubMed citation query: 'Semin Oncol||29|11||bib10|'--></citation></ref><ref id="bib11"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Cheng</surname><given-names>AL</given-names></name><name><surname>Yeh</surname><given-names>KH</given-names></name><name><surname>Lin</surname><given-names>JT</given-names></name><name><surname>Hsu</surname><given-names>C</given-names></name><name><surname>Liu</surname><given-names>MY</given-names></name></person-group><article-title>Cisplatin, etoposide, and weekly high-dose 5-fluorouracil and leucovorin infusion (PE-HDFL) &#x02013; a very effective regimen with good patients' compliance for advanced gastric cancer</article-title><source>Anticancer Res</source><year>1998</year><volume>18</volume><fpage>1267</fpage><lpage>1272</lpage><!--PubMed citation query: 'Anticancer Res||18|1267||bib11|'--><pub-id pub-id-type="pmid">9615799</pub-id></citation></ref><ref id="bib12"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Chi</surname><given-names>KH</given-names></name><name><surname>Chao</surname><given-names>Y</given-names></name><name><surname>Chan</surname><given-names>WK</given-names></name><name><surname>Lo</surname><given-names>SS</given-names></name><name><surname>Chen</surname><given-names>SY</given-names></name><name><surname>Yen</surname><given-names>SH</given-names></name><name><surname>Chen</surname><given-names>KY</given-names></name><name><surname>Wu</surname><given-names>CW</given-names></name><name><surname>Lee</surname><given-names>SD</given-names></name><name><surname>Lui</surname><given-names>WY</given-names></name></person-group><article-title>Weekly etoposide, epirubicin, cisplatin, 5-fluorouracil and leucovorin: an effective chemotherapy in advanced gastric cancer</article-title><source>Br J Cancer</source><year>1998</year><volume>77</volume><fpage>1984</fpage><lpage>1988</lpage><!--PubMed citation query: 'Br J Cancer||77|1984||bib12|'--><pub-id pub-id-type="pmid">9667679</pub-id></citation></ref><ref id="bib13"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Cocconi</surname><given-names>G</given-names></name><name><surname>Bella</surname><given-names>M</given-names></name><name><surname>Zironi</surname><given-names>S</given-names></name><name><surname>Algeri</surname><given-names>R</given-names></name><name><surname>Di Costanzo</surname><given-names>F</given-names></name><name><surname>De Lisi</surname><given-names>V</given-names></name><name><surname>Luppi</surname><given-names>G</given-names></name><name><surname>Mazzocchi</surname><given-names>B</given-names></name><name><surname>Rodino</surname><given-names>C</given-names></name><name><surname>Soldani</surname><given-names>M</given-names></name></person-group><article-title>Fluorouracil, doxorubicin, and mitomycin combination versus PELF chemotherapy in advanced gastric cancer: a prospective randomized trial of the Italian Oncology Group for Clinical Research</article-title><source>J Clin Oncol</source><year>1994</year><volume>12</volume><fpage>2687</fpage><lpage>2693</lpage><!--PubMed citation query: 'J Clin Oncol||12|2687||bib13|'--><pub-id pub-id-type="pmid">7989945</pub-id></citation></ref><ref id="bib14"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>de Gramont</surname><given-names>A</given-names></name><name><surname>Figer</surname><given-names>A</given-names></name><name><surname>Seymour</surname><given-names>M</given-names></name><name><surname>Homerin</surname><given-names>M</given-names></name><name><surname>Hmissi</surname><given-names>A</given-names></name><name><surname>Cassidy</surname><given-names>J</given-names></name><name><surname>Boni</surname><given-names>C</given-names></name><name><surname>Cortes-Funes</surname><given-names>H</given-names></name><name><surname>Cervantes</surname><given-names>A</given-names></name><name><surname>Freyer</surname><given-names>G</given-names></name><name><surname>Papamichael</surname><given-names>D</given-names></name><name><surname>Le Bail</surname><given-names>N</given-names></name><name><surname>Louvet</surname><given-names>C</given-names></name><name><surname>Hendler</surname><given-names>D</given-names></name><name><surname>de Braud</surname><given-names>F</given-names></name><name><surname>Wilson</surname><given-names>C</given-names></name><name><surname>Morvan</surname><given-names>F</given-names></name><name><surname>Bonetti</surname><given-names>A</given-names></name></person-group><article-title>Leucovorin and fluorouracil with or without oxaliplatin as first-line treatment in advanced colorectal cancer</article-title><source>J Clin Oncol</source><year>2000</year><volume>18</volume><fpage>2938</fpage><lpage>2947</lpage><!--PubMed citation query: 'J Clin Oncol||18|2938||bib14|'--><pub-id pub-id-type="pmid">10944126</pub-id></citation></ref><ref id="bib15"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>De Vivo</surname><given-names>R</given-names></name><name><surname>Pignata</surname><given-names>S</given-names></name><name><surname>Palaia</surname><given-names>R</given-names></name><name><surname>Parisi</surname><given-names>V</given-names></name><name><surname>Daniele</surname><given-names>B</given-names></name></person-group><article-title>The role of chemotherapy in the management of gastric cancer</article-title><source>J Clin Gastroenterol</source><year>2000</year><volume>30</volume><fpage>364</fpage><lpage>371</lpage><!--PubMed citation query: 'J Clin Gastroenterol||30|364||bib15|'--><pub-id pub-id-type="pmid">10875463</pub-id></citation></ref><ref id="bib16"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Di Francesco</surname><given-names>AM</given-names></name><name><surname>Ruggiero</surname><given-names>A</given-names></name><name><surname>Riccardi</surname><given-names>R</given-names></name></person-group><article-title>Cellular and molecular aspects of drugs of the future: oxaliplatin</article-title><source>Cell Mol Life Sci</source><year>2002</year><volume>59</volume><fpage>1914</fpage><lpage>1927</lpage><!--PubMed citation query: 'Cell Mol Life Sci||59|1914||bib16|'--><pub-id pub-id-type="pmid">12530522</pub-id></citation></ref><ref id="bib17"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Findlay</surname><given-names>M</given-names></name><name><surname>Cunningham</surname><given-names>D</given-names></name></person-group><article-title>Chemotherapy of carcinoma of the stomach</article-title><source>Cancer Treat Rev</source><year>1993</year><volume>19</volume><fpage>29</fpage><lpage>44</lpage><!--PubMed citation query: 'Cancer Treat Rev||19|29||bib17|'--></citation></ref><ref id="bib18"><citation citation-type="book"><person-group person-group-type="author"><name><surname>Ho</surname><given-names>D</given-names></name></person-group><article-title>Epidemiologic studies in gastric cancer</article-title><source>Gastric Cancer</source><year>1988</year><publisher-name>New York, NY: Churchill Livingstone</publisher-name><fpage>1</fpage><lpage>25</lpage></citation></ref><ref id="bib19"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Hsu</surname><given-names>CH</given-names></name><name><surname>Yeh</surname><given-names>KH</given-names></name><name><surname>Chen</surname><given-names>LT</given-names></name><name><surname>Liu</surname><given-names>JM</given-names></name><name><surname>Jan</surname><given-names>CM</given-names></name><name><surname>Lin</surname><given-names>JT</given-names></name><name><surname>Chen</surname><given-names>YC</given-names></name><name><surname>Cheng</surname><given-names>AL</given-names></name></person-group><article-title>Weekly 24-hour infusion of high-dose 5-fluorouracil and leucovorin in the treatment of advanced gastric cancers &#x02013; an effective and low-toxic regimen for patients with poor general condition</article-title><source>Oncology</source><year>1997</year><volume>54</volume><fpage>275</fpage><lpage>280</lpage><!--PubMed citation query: 'Oncology||54|275||bib19|'--><pub-id pub-id-type="pmid">9216850</pub-id></citation></ref><ref id="bib20"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Hsu</surname><given-names>CH</given-names></name><name><surname>Yeh</surname><given-names>KH</given-names></name><name><surname>Yeh</surname><given-names>PY</given-names></name><name><surname>Chen</surname><given-names>ML</given-names></name><name><surname>Lin</surname><given-names>ZR</given-names></name><name><surname>Cheng</surname><given-names>AL</given-names></name></person-group><article-title>Cytotoxicity of oxaliplatin in gastric cancer cells &#x02013; studies on single-agent activity and combination effect with 5-fluorouracil</article-title><source>Proc Am Assoc Cancer Res</source><year>2000</year><volume>41</volume><fpage>517</fpage>abstract 3295<!--PubMed citation query: 'Proc Am Assoc Cancer Res||41|517||bib20|'--></citation></ref><ref id="bib21"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Johnson</surname><given-names>PW</given-names></name><name><surname>Thompson</surname><given-names>PI</given-names></name><name><surname>Seymour</surname><given-names>MT</given-names></name><name><surname>Deasy</surname><given-names>NP</given-names></name><name><surname>Thuraisingham</surname><given-names>RC</given-names></name><name><surname>Slevin</surname><given-names>ML</given-names></name><name><surname>Wrigley</surname><given-names>PF</given-names></name></person-group><article-title>A less toxic regimen of 5-fluorouracil and high-dose folinic acid for advanced gastrointestinal adenocarcinomas</article-title><source>Br J Cancer</source><year>1991</year><volume>64</volume><fpage>603</fpage><lpage>605</lpage><!--PubMed citation query: 'Br J Cancer||64|603||bib21|'--><pub-id pub-id-type="pmid">1911206</pub-id></citation></ref><ref id="bib22"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Kelsen</surname><given-names>D</given-names></name><name><surname>Atiq</surname><given-names>OT</given-names></name><name><surname>Saltz</surname><given-names>L</given-names></name><name><surname>Niedzwiecki</surname><given-names>D</given-names></name><name><surname>Ginn</surname><given-names>D</given-names></name><name><surname>Chapman</surname><given-names>D</given-names></name><name><surname>Heelan</surname><given-names>R</given-names></name><name><surname>Lightdale</surname><given-names>C</given-names></name><name><surname>Vinciguerra</surname><given-names>V</given-names></name><name><surname>Brennan</surname><given-names>M</given-names></name></person-group><article-title>FAMTX versus etoposide, doxorubicin, and cisplatin: a random assignment trial in gastric cancer</article-title><source>J Clin Oncol</source><year>1992</year><volume>10</volume><fpage>541</fpage><lpage>548</lpage><!--PubMed citation query: 'J Clin Oncol||10|541||bib22|'--><pub-id pub-id-type="pmid">1548519</pub-id></citation></ref><ref id="bib23"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Kim</surname><given-names>DY</given-names></name><name><surname>Kim</surname><given-names>JH</given-names></name><name><surname>Lee</surname><given-names>SH</given-names></name><name><surname>Kim</surname><given-names>TY</given-names></name><name><surname>Heo</surname><given-names>DS</given-names></name><name><surname>Bang</surname><given-names>YJ</given-names></name><name><surname>Kim</surname><given-names>NK</given-names></name></person-group><article-title>Phase II study of oxaliplatin, 5-fluorouracil and leucovorin in previously platinum-treated patients with advanced gastric cancer</article-title><source>Ann Oncol</source><year>2003</year><volume>14</volume><fpage>383</fpage><lpage>387</lpage><!--PubMed citation query: 'Ann Oncol||14|383||bib23|'--><pub-id pub-id-type="pmid">12598342</pub-id></citation></ref><ref id="bib24"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Kim</surname><given-names>NK</given-names></name><name><surname>Park</surname><given-names>YS</given-names></name><name><surname>Heo</surname><given-names>DS</given-names></name><name><surname>Suh</surname><given-names>C</given-names></name><name><surname>Kim</surname><given-names>SY</given-names></name><name><surname>Park</surname><given-names>KC</given-names></name><name><surname>Kang</surname><given-names>YK</given-names></name><name><surname>Shin</surname><given-names>DB</given-names></name><name><surname>Kim</surname><given-names>HT</given-names></name><name><surname>Kim</surname><given-names>HJ</given-names></name></person-group><article-title>A phase III randomized study of 5-fluorouracil and cisplatin versus 5-fluorouracil, doxorubicin, and mitomycin C versus 5-fluorouracil alone in the treatment of advanced gastric cancer</article-title><source>Cancer</source><year>1993</year><volume>71</volume><fpage>3813</fpage><lpage>3818</lpage><!--PubMed citation query: 'Cancer||71|3813||bib24|'--><pub-id pub-id-type="pmid">8508349</pub-id></citation></ref><ref id="bib25"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Kohne</surname><given-names>CH</given-names></name><name><surname>Wils</surname><given-names>J</given-names></name><name><surname>Lorenz</surname><given-names>M</given-names></name><name><surname>Schoffski</surname><given-names>P</given-names></name><name><surname>Voigtmann</surname><given-names>R</given-names></name><name><surname>Bokemeyer</surname><given-names>C</given-names></name><name><surname>Lutz</surname><given-names>M</given-names></name><name><surname>Kleeberg</surname><given-names>C</given-names></name><name><surname>Ridwelski</surname><given-names>K</given-names></name><name><surname>Souchon</surname><given-names>R</given-names></name><name><surname>El-Serafi</surname><given-names>M</given-names></name><name><surname>Weiss</surname><given-names>U</given-names></name><name><surname>Burkhard</surname><given-names>O</given-names></name><name><surname>Ruckle</surname><given-names>H</given-names></name><name><surname>Lichnitser</surname><given-names>M</given-names></name><name><surname>Langenbuch</surname><given-names>T</given-names></name><name><surname>Scheithauer</surname><given-names>W</given-names></name><name><surname>Baron</surname><given-names>B</given-names></name><name><surname>Couvreur</surname><given-names>ML</given-names></name><name><surname>Schmoll</surname><given-names>HJ</given-names></name></person-group><article-title>Randomized phase III study of high-dose fluorouracil given as a weekly 24-hour infusion with or without leucovorin versus bolus fluorouracil plus leucovorin in advanced colorectal cancer: European organization of Research and Treatment of Cancer Gastrointestinal Group Study 40952</article-title><source>J Clin Oncol</source><year>2003</year><volume>21</volume><fpage>3721</fpage><lpage>3728</lpage><!--PubMed citation query: 'J Clin Oncol||21|3721||bib25|'--><pub-id pub-id-type="pmid">12963704</pub-id></citation></ref><ref id="bib26"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Kollmannsberger</surname><given-names>C</given-names></name><name><surname>Quietzsch</surname><given-names>D</given-names></name><name><surname>Haag</surname><given-names>C</given-names></name><name><surname>Lingenfelser</surname><given-names>T</given-names></name><name><surname>Schroeder</surname><given-names>M</given-names></name><name><surname>Hartmann</surname><given-names>JT</given-names></name><name><surname>Baronius</surname><given-names>W</given-names></name><name><surname>Hempel</surname><given-names>V</given-names></name><name><surname>Clemens</surname><given-names>M</given-names></name><name><surname>Kanz</surname><given-names>L</given-names></name><name><surname>Bokemeyer</surname><given-names>C</given-names></name></person-group><article-title>A phase II study of paclitaxel, weekly, 24-hour continuous infusion 5-fluorouracil, folinic acid and cisplatin in patients with advanced gastric cancer</article-title><source>Br J Cancer</source><year>2000</year><volume>83</volume><fpage>458</fpage><lpage>462</lpage><!--PubMed citation query: 'Br J Cancer||83|458||bib26|'--><pub-id pub-id-type="pmid">10945491</pub-id></citation></ref><ref id="bib27"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Kollmannsberger</surname><given-names>C</given-names></name><name><surname>Rick</surname><given-names>O</given-names></name><name><surname>Derigs</surname><given-names>HG</given-names></name><name><surname>Schleucher</surname><given-names>N</given-names></name><name><surname>Schoffski</surname><given-names>P</given-names></name><name><surname>Beyer</surname><given-names>J</given-names></name><name><surname>Schoch</surname><given-names>R</given-names></name><name><surname>Sayer</surname><given-names>HG</given-names></name><name><surname>Gerl</surname><given-names>A</given-names></name><name><surname>Kuczyk</surname><given-names>M</given-names></name><name><surname>Spott</surname><given-names>C</given-names></name><name><surname>Kanz</surname><given-names>L</given-names></name><name><surname>Bokemeyer</surname><given-names>C</given-names></name></person-group><article-title>Activity of oxaliplatin in patients with relapsed or cisplatin-refractory germ cell cancer: a study of the German Testicular Cancer Study Group</article-title><source>J Clin Oncol</source><year>2002</year><volume>20</volume><fpage>2031</fpage><lpage>2037</lpage><!--PubMed citation query: 'J Clin Oncol||20|2031||bib27|'--><pub-id pub-id-type="pmid">11956262</pub-id></citation></ref><ref id="bib28"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Louvet</surname><given-names>C</given-names></name><name><surname>Andre</surname><given-names>T</given-names></name><name><surname>Tigaud</surname><given-names>JM</given-names></name><name><surname>Gamelin</surname><given-names>E</given-names></name><name><surname>Douillard</surname><given-names>JY</given-names></name><name><surname>Brunet</surname><given-names>R</given-names></name><name><surname>Francois</surname><given-names>E</given-names></name><name><surname>Jacob</surname><given-names>JH</given-names></name><name><surname>Levoir</surname><given-names>D</given-names></name><name><surname>Taamma</surname><given-names>A</given-names></name><name><surname>Rougier</surname><given-names>P</given-names></name><name><surname>Cvitkovic</surname><given-names>E</given-names></name><name><surname>de Gramont</surname><given-names>A</given-names></name></person-group><article-title>Phase II study of oxaliplatin, fluorouracil, and folinic acid in locally advanced or metastatic gastric cancer patients</article-title><source>J Clin Oncol</source><year>2002</year><volume>20</volume><fpage>4543</fpage><lpage>4548</lpage><!--PubMed citation query: 'J Clin Oncol||20|4543||bib28|'--><pub-id pub-id-type="pmid">12454110</pub-id></citation></ref><ref id="bib29"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Louvet</surname><given-names>C</given-names></name><name><surname>de Gramont</surname><given-names>A</given-names></name><name><surname>Demuynck</surname><given-names>B</given-names></name><name><surname>Nordlinger</surname><given-names>B</given-names></name><name><surname>Maisani</surname><given-names>JE</given-names></name><name><surname>Lagadec</surname><given-names>B</given-names></name><name><surname>Delfau</surname><given-names>S</given-names></name><name><surname>Varette</surname><given-names>C</given-names></name><name><surname>Gonzalez-Canali</surname><given-names>G</given-names></name><name><surname>Krulik</surname><given-names>M</given-names></name></person-group><article-title>High-dose folinic acid, 5-fluorouracil bolus and continuous infusion in poor-prognosis patients with advanced measurable gastric cancer</article-title><source>Ann Oncol</source><year>1991</year><volume>2</volume><fpage>229</fpage><lpage>230</lpage><!--PubMed citation query: 'Ann Oncol||2|229||bib29|'--><pub-id pub-id-type="pmid">2043494</pub-id></citation></ref><ref id="bib30"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>MacDonald</surname><given-names>JS</given-names></name><name><surname>Schein</surname><given-names>PS</given-names></name><name><surname>Woolley</surname><given-names>PV</given-names></name><name><surname>Smythe</surname><given-names>T</given-names></name><name><surname>Ueno</surname><given-names>W</given-names></name><name><surname>Hoth</surname><given-names>D</given-names></name><name><surname>Smith</surname><given-names>F</given-names></name><name><surname>Boiron</surname><given-names>M</given-names></name><name><surname>Gisselbrecht</surname><given-names>C</given-names></name><name><surname>Brunet</surname><given-names>R</given-names></name><name><surname>Lagarde</surname><given-names>C</given-names></name></person-group><article-title>5-Fluorouracil, doxorubicin, and mitomycin (FAM) combination chemotherapy for advanced gastric cancer</article-title><source>Ann Intern Med</source><year>1980</year><volume>93</volume><fpage>533</fpage><lpage>536</lpage><!--PubMed citation query: 'Ann Intern Med||93|533||bib30|'--><pub-id pub-id-type="pmid">7436184</pub-id></citation></ref><ref id="bib31"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Machover</surname><given-names>D</given-names></name><name><surname>Diaz-Rubio</surname><given-names>E</given-names></name><name><surname>de Gramont</surname><given-names>A</given-names></name><name><surname>Schilf</surname><given-names>A</given-names></name><name><surname>Gastiaburu</surname><given-names>JJ</given-names></name><name><surname>Brienza</surname><given-names>S</given-names></name><name><surname>Itzhaki</surname><given-names>M</given-names></name><name><surname>Metzger</surname><given-names>G</given-names></name><name><surname>N'Daw</surname><given-names>D</given-names></name><name><surname>Vignoud</surname><given-names>J</given-names></name><name><surname>Abad</surname><given-names>A</given-names></name><name><surname>Francois</surname><given-names>E</given-names></name><name><surname>Gamelin</surname><given-names>E</given-names></name><name><surname>Marty</surname><given-names>M</given-names></name><name><surname>Sastre</surname><given-names>J</given-names></name><name><surname>Seitz</surname><given-names>JF</given-names></name><name><surname>Ychou</surname><given-names>M</given-names></name></person-group><article-title>Two consecutive phase II studies of oxaliplatin (L-OHP) for treatment of patients with advanced colorectal carcinoma who were resistant to previous treatment with fluoropyrimidines</article-title><source>Ann Oncol</source><year>1996</year><volume>7</volume><fpage>95</fpage><lpage>98</lpage><!--PubMed citation query: 'Ann Oncol||7|95||bib31|'--></citation></ref><ref id="bib32"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Misset</surname><given-names>JL</given-names></name><name><surname>Vennin</surname><given-names>P</given-names></name><name><surname>Chollet</surname><given-names>PH</given-names></name><name><surname>Pouillart</surname><given-names>P</given-names></name><name><surname>Laplaige</surname><given-names>PH</given-names></name><name><surname>Frobert</surname><given-names>JL</given-names></name><name><surname>Castera</surname><given-names>D</given-names></name><name><surname>Fabro</surname><given-names>M</given-names></name><name><surname>Langlois</surname><given-names>D</given-names></name><name><surname>Cortesi</surname><given-names>E</given-names></name><name><surname>Lucas</surname><given-names>V</given-names></name><name><surname>Gamelin</surname><given-names>E</given-names></name><name><surname>Laadem</surname><given-names>A</given-names></name><name><surname>Otero</surname><given-names>J</given-names></name></person-group><article-title>Multicenter phase II&#x02013;III study of oxaliplatin plus cyclophosphamide <italic>vs</italic> cisplatin plus cyclophosphamide in chemonaive advanced ovarian cancer patients</article-title><source>Ann Oncol</source><year>2001</year><volume>12</volume><fpage>1411</fpage><lpage>1415</lpage><!--PubMed citation query: 'Ann Oncol||12|1411||bib32|'--><pub-id pub-id-type="pmid">11762813</pub-id></citation></ref><ref id="bib33"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Monnet</surname><given-names>I</given-names></name><name><surname>Brienza</surname><given-names>S</given-names></name><name><surname>Hugret</surname><given-names>F</given-names></name><name><surname>Voisin</surname><given-names>S</given-names></name><name><surname>Gastiaburu</surname><given-names>J</given-names></name><name><surname>Saltiel</surname><given-names>JC</given-names></name><name><surname>Soulie</surname><given-names>P</given-names></name><name><surname>Armand</surname><given-names>JP</given-names></name><name><surname>Cvitkovic</surname><given-names>E</given-names></name><name><surname>de Cremoux</surname><given-names>H</given-names></name></person-group><article-title>Phase II study of oxaliplatin in poor-prognosis non-small cell lung cancer (NSCLC). ATTIT. Association pour le Traitement es Tumeurs Intra Thoraciques</article-title><source>Eur J Cancer</source><year>1998</year><volume>34</volume><fpage>1124</fpage><lpage>1127</lpage><!--PubMed citation query: 'Eur J Cancer||34|1124||bib33|'--><pub-id pub-id-type="pmid">9849465</pub-id></citation></ref><ref id="bib34"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Ohtsu</surname><given-names>A</given-names></name><name><surname>Shimada</surname><given-names>Y</given-names></name><name><surname>Shirao</surname><given-names>K</given-names></name><name><surname>Boku</surname><given-names>N</given-names></name><name><surname>Hyodo</surname><given-names>I</given-names></name><name><surname>Saito</surname><given-names>H</given-names></name><name><surname>Yamamichi</surname><given-names>N</given-names></name><name><surname>Miyata</surname><given-names>Y</given-names></name><name><surname>Ikeda</surname><given-names>N</given-names></name><name><surname>Yamamoto</surname><given-names>S</given-names></name><name><surname>Fukuda</surname><given-names>H</given-names></name><name><surname>Yoshida</surname><given-names>S</given-names></name></person-group><article-title>Randomized phase III trial of fluorouracil alone versus fluorouracil plus cisplatin versus uracil and tegafur plus mitomycin in patients with unresectable, advanced gastric cancer: The Japan Clinical Oncology Group Study (JCOG9205)</article-title><source>J Clin Oncol</source><year>2003</year><volume>21</volume><fpage>54</fpage><lpage>59</lpage><!--PubMed citation query: 'J Clin Oncol||21|54||bib34|'--><pub-id pub-id-type="pmid">12506170</pub-id></citation></ref><ref id="bib35"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Pendyala</surname><given-names>L</given-names></name><name><surname>Creaven</surname><given-names>PJ</given-names></name></person-group><article-title><italic>In vitro</italic> cytotoxicity, protein binding, red blood cell partitioning, and biotransformation of oxaliplatin</article-title><source>Cancer Res</source><year>1993</year><volume>53</volume><fpage>5970</fpage><lpage>5976</lpage><!--PubMed citation query: 'Cancer Res||53|5970||bib35|'--><pub-id pub-id-type="pmid">8261411</pub-id></citation></ref><ref id="bib36"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Preusser</surname><given-names>P</given-names></name><name><surname>Wilke</surname><given-names>H</given-names></name><name><surname>Achterrath</surname><given-names>W</given-names></name><name><surname>Fink</surname><given-names>U</given-names></name><name><surname>Lenaz</surname><given-names>L</given-names></name><name><surname>Heinicke</surname><given-names>A</given-names></name><name><surname>Meyer</surname><given-names>J</given-names></name><name><surname>Meyer</surname><given-names>HJ</given-names></name><name><surname>Buente</surname><given-names>H</given-names></name></person-group><article-title>Phase II study with the combination etoposide, doxorubicin, and cisplatin in advanced measurable gastric cancer</article-title><source>J Clin Oncol</source><year>1989</year><volume>7</volume><fpage>1310</fpage><lpage>1317</lpage><!--PubMed citation query: 'J Clin Oncol||7|1310||bib36|'--><pub-id pub-id-type="pmid">2671287</pub-id></citation></ref><ref id="bib37"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Roder</surname><given-names>DM</given-names></name></person-group><article-title>The epidemiology of gastric cancer</article-title><source>Gastric Cancer</source><year>2002</year><volume>5</volume><supplement>Suppl 1</supplement><fpage>5</fpage><lpage>11</lpage><!--PubMed citation query: 'Gastric Cancer||5|5||bib37|'--><pub-id pub-id-type="pmid">12772880</pub-id></citation></ref><ref id="bib38"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Slater</surname><given-names>S</given-names></name><name><surname>Shamash</surname><given-names>J</given-names></name><name><surname>Wilson</surname><given-names>P</given-names></name><name><surname>Gallagher</surname><given-names>CJ</given-names></name><name><surname>Slevin</surname><given-names>ML</given-names></name></person-group><article-title>Irinotecan, cisplatin and mitomycin in inoperable gastro-oesophageal and pancreatic cancers &#x02013; a new active regimen</article-title><source>Br J Cancer</source><year>2002</year><volume>87</volume><fpage>850</fpage><lpage>853</lpage><!--PubMed citation query: 'Br J Cancer||87|850||bib38|'--><pub-id pub-id-type="pmid">12373598</pub-id></citation></ref><ref id="bib39"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Sumpter</surname><given-names>KA</given-names></name><name><surname>Harper-Wynne</surname><given-names>C</given-names></name><name><surname>Cunningham</surname><given-names>D</given-names></name><name><surname>Oates</surname><given-names>J</given-names></name><name><surname>Tebbutt</surname><given-names>N</given-names></name><name><surname>Iveson</surname><given-names>T</given-names></name><name><surname>Nicolson</surname><given-names>M</given-names></name><name><surname>Hickish</surname><given-names>T</given-names></name><name><surname>Hill</surname><given-names>M</given-names></name><name><surname>Norman</surname><given-names>A</given-names></name></person-group><article-title>Randomised, multicenter phase III study comparing capecitabine with fluorouracil and oxaliplatin with cisplatin in patients with advanced oesophagogastric cancer: confirmation of dose escalation</article-title><source>Proc Am Soc Clin Oncol</source><year>2003</year><volume>22</volume><fpage>257</fpage>abstract 1031<!--PubMed citation query: 'Proc Am Soc Clin Oncol||22|257||bib39|'--></citation></ref><ref id="bib40"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Vanhoefer</surname><given-names>U</given-names></name><name><surname>Rougier</surname><given-names>P</given-names></name><name><surname>Wilke</surname><given-names>H</given-names></name><name><surname>Ducreux</surname><given-names>MP</given-names></name><name><surname>Lacave</surname><given-names>AJ</given-names></name><name><surname>Van Cutsem</surname><given-names>E</given-names></name><name><surname>Planker</surname><given-names>M</given-names></name><name><surname>Santos</surname><given-names>JG</given-names></name><name><surname>Piedbois</surname><given-names>P</given-names></name><name><surname>Paillot</surname><given-names>B</given-names></name><name><surname>Bodenstein</surname><given-names>H</given-names></name><name><surname>Schmoll</surname><given-names>HJ</given-names></name><name><surname>Bleiberg</surname><given-names>H</given-names></name><name><surname>Nordlinger</surname><given-names>B</given-names></name><name><surname>Couvreur</surname><given-names>ML</given-names></name><name><surname>Baron</surname><given-names>B</given-names></name><name><surname>Wils</surname><given-names>JA</given-names></name></person-group><article-title>Final results of a randomized phase III trial of sequential high-dose methotrexate, fluorouracil, and doxorubicin versus etoposide, leucovorin, and fluorouracil versus infusional fluorouracil and cisplatin in advanced gastric cancer: a trial of the European Organization for Research and Treatment of Cancer Gastrointestinal Tract Cancer Cooperative Group</article-title><source>J Clin Oncol</source><year>2000</year><volume>18</volume><fpage>2648</fpage><lpage>2657</lpage><!--PubMed citation query: 'J Clin Oncol||18|2648||bib40|'--><pub-id pub-id-type="pmid">10894863</pub-id></citation></ref><ref id="bib41"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Vanhoefer</surname><given-names>U</given-names></name><name><surname>Wilke</surname><given-names>H</given-names></name><name><surname>Weh</surname><given-names>HJ</given-names></name><name><surname>Clemens</surname><given-names>M</given-names></name><name><surname>Harstrick</surname><given-names>A</given-names></name><name><surname>Stahl</surname><given-names>M</given-names></name><name><surname>Hossfeld</surname><given-names>DK</given-names></name><name><surname>Seeber</surname><given-names>S</given-names></name></person-group><article-title>Weekly high-dose 5-fluorouracil and folinic acid as salvage treatment in advanced gastric cancer</article-title><source>Ann Oncol</source><year>1994</year><volume>5</volume><fpage>850</fpage><lpage>851</lpage><!--PubMed citation query: 'Ann Oncol||5|850||bib41|'--><pub-id pub-id-type="pmid">7848888</pub-id></citation></ref><ref id="bib42"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Waters</surname><given-names>JS</given-names></name><name><surname>Norman</surname><given-names>A</given-names></name><name><surname>Cunningham</surname><given-names>D</given-names></name><name><surname>Scarffe</surname><given-names>JH</given-names></name><name><surname>Webb</surname><given-names>A</given-names></name><name><surname>Harper</surname><given-names>P</given-names></name><name><surname>Joffe</surname><given-names>JK</given-names></name><name><surname>Mackean</surname><given-names>M</given-names></name><name><surname>Mansi</surname><given-names>J</given-names></name><name><surname>Leahy</surname><given-names>M</given-names></name><name><surname>Hill</surname><given-names>A</given-names></name><name><surname>Oates</surname><given-names>J</given-names></name><name><surname>Rao</surname><given-names>S</given-names></name><name><surname>Nicolson</surname><given-names>M</given-names></name><name><surname>Hickish</surname><given-names>T</given-names></name></person-group><article-title>Long-term survival after epirubicin, cisplatin and fluorouracil for gastric cancer: results of a randomized trial</article-title><source>Br J Cancer</source><year>1999</year><volume>80</volume><fpage>269</fpage><lpage>272</lpage><!--PubMed citation query: 'Br J Cancer||80|269||bib42|'--><pub-id pub-id-type="pmid">10390007</pub-id></citation></ref><ref id="bib43"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Webb</surname><given-names>A</given-names></name><name><surname>Cunningham</surname><given-names>D</given-names></name><name><surname>Scarffe</surname><given-names>JH</given-names></name><name><surname>Harper</surname><given-names>P</given-names></name><name><surname>Norman</surname><given-names>A</given-names></name><name><surname>Joffe</surname><given-names>JK</given-names></name><name><surname>Hughes</surname><given-names>M</given-names></name><name><surname>Mansi</surname><given-names>J</given-names></name><name><surname>Findlay</surname><given-names>M</given-names></name><name><surname>Hill</surname><given-names>A</given-names></name><name><surname>Oates</surname><given-names>J</given-names></name><name><surname>Nicolson</surname><given-names>M</given-names></name><name><surname>Hickish</surname><given-names>T</given-names></name><name><surname>O'Brien</surname><given-names>M</given-names></name><name><surname>Iveson</surname><given-names>T</given-names></name><name><surname>Watson</surname><given-names>M</given-names></name><name><surname>Underhill</surname><given-names>C</given-names></name><name><surname>Wardley</surname><given-names>A</given-names></name><name><surname>Meehan</surname><given-names>M</given-names></name></person-group><article-title>Randomized trial comparing epirubicin, cisplatin, and fluorouracil versus fluorouracil, doxorubicin, and methotrexate in advanced esophagogastric cancer</article-title><source>J Clin Oncol</source><year>1997</year><volume>15</volume><fpage>261</fpage><lpage>267</lpage><!--PubMed citation query: 'J Clin Oncol||15|261||bib43|'--><pub-id pub-id-type="pmid">8996151</pub-id></citation></ref><ref id="bib44"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Wilke</surname><given-names>H</given-names></name><name><surname>Preusser</surname><given-names>P</given-names></name><name><surname>Fink</surname><given-names>U</given-names></name><name><surname>Achterrath</surname><given-names>W</given-names></name><name><surname>Lenaz</surname><given-names>L</given-names></name><name><surname>Stahl</surname><given-names>M</given-names></name><name><surname>Schober</surname><given-names>C</given-names></name><name><surname>Link</surname><given-names>H</given-names></name><name><surname>Meyer</surname><given-names>HJ</given-names></name><name><surname>Lucke</surname><given-names>B</given-names></name></person-group><article-title>High dose folinic acid&#x0002f;etoposide&#x0002f;5-fluorouracil in advanced gastric cancer &#x02013; a phase II study in elderly patients or patients with cardiac risk</article-title><source>Invest New Drugs</source><year>1990</year><volume>8</volume><fpage>65</fpage><lpage>70</lpage><!--PubMed citation query: 'Invest New Drugs||8|65||bib44|'--><pub-id pub-id-type="pmid">2345071</pub-id></citation></ref><ref id="bib45"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Wils</surname><given-names>J</given-names></name></person-group><article-title>The treatment of advanced gastric cancer</article-title><source>Semin Oncol</source><year>1996</year><volume>23</volume><fpage>397</fpage><lpage>406</lpage><!--PubMed citation query: 'Semin Oncol||23|397||bib45|'--><pub-id pub-id-type="pmid">8658224</pub-id></citation></ref><ref id="bib46"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Wils</surname><given-names>JA</given-names></name><name><surname>Klein</surname><given-names>HO</given-names></name><name><surname>Wagener</surname><given-names>DJ</given-names></name><name><surname>Bleiberg</surname><given-names>H</given-names></name><name><surname>Reis</surname><given-names>H</given-names></name><name><surname>Korsten</surname><given-names>F</given-names></name><name><surname>Conroy</surname><given-names>T</given-names></name><name><surname>Fickers</surname><given-names>M</given-names></name><name><surname>Leyvraz</surname><given-names>S</given-names></name><name><surname>Buyse</surname><given-names>M</given-names></name></person-group><article-title>Sequential high-dose methotrexate and fluorouracil combined with doxorubicin &#x02013; a step ahead in the treatment of advanced gastric cancer: a trial of the European Organization for Research and Treatment of Cancer Gastrointestinal Tract Cooperative Group</article-title><source>J Clin Oncol</source><year>1991</year><volume>9</volume><fpage>827</fpage><lpage>831</lpage><!--PubMed citation query: 'J Clin Oncol||9|827||bib46|'--><pub-id pub-id-type="pmid">2016625</pub-id></citation></ref><ref id="bib47"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Ychou</surname><given-names>M</given-names></name><name><surname>Astre</surname><given-names>C</given-names></name><name><surname>Rouanet</surname><given-names>P</given-names></name><name><surname>Fabre</surname><given-names>JM</given-names></name><name><surname>Saint-Aubert</surname><given-names>B</given-names></name><name><surname>Domergue</surname><given-names>J</given-names></name><name><surname>Ribard</surname><given-names>D</given-names></name><name><surname>Ciurana</surname><given-names>AJ</given-names></name><name><surname>Janbon</surname><given-names>C</given-names></name><name><surname>Pujol</surname><given-names>H</given-names></name></person-group><article-title>A phase II study of 5-fluorouracil, leucovorin and cisplatin (FLP) for metastatic gastric cancer</article-title><source>Eur J Cancer</source><year>1996</year><volume>32A</volume><fpage>1933</fpage><lpage>1937</lpage><!--PubMed citation query: 'Eur J Cancer||32A|1933||bib47|'--><pub-id pub-id-type="pmid">8943677</pub-id></citation></ref><ref id="bib48"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Yeh</surname><given-names>KH</given-names></name><name><surname>Cheng</surname><given-names>AL</given-names></name></person-group><article-title>An alternative method to overcome central venous portable external infusion pump blockage in patients receiving weekly 24-hour high-dose fluorouracil and leucovorin</article-title><source>J Clin Oncol</source><year>1994</year><volume>12</volume><fpage>875</fpage><lpage>876</lpage><!--PubMed citation query: 'J Clin Oncol||12|875||bib48|'--><pub-id pub-id-type="pmid">8151330</pub-id></citation></ref><ref id="bib49"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Yeh</surname><given-names>KH</given-names></name><name><surname>Cheng</surname><given-names>AL</given-names></name></person-group><article-title>High-dose 5-fluorouracil infusional therapy is associated with hyperammonaemia, lactic acidosis and encephalopathy</article-title><source>Br J Cancer</source><year>1997</year><volume>75</volume><fpage>464</fpage><lpage>465</lpage><!--PubMed citation query: 'Br J Cancer||75|464||bib49|'--></citation></ref><ref id="bib50"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Yeh</surname><given-names>KH</given-names></name><name><surname>Cheng</surname><given-names>AL</given-names></name></person-group><article-title>Gastric cancer associated with acute disseminated intravascular coagulation: successful initial treatment with weekly 24-hour infusion of high-dose 5-fluorouracil and leucovorin</article-title><source>Br J Haematol</source><year>1998</year><volume>100</volume><fpage>769</fpage><lpage>772</lpage><!--PubMed citation query: 'Br J Haematol||100|769||bib50|'--><pub-id pub-id-type="pmid">9531347</pub-id></citation></ref><ref id="bib51"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Yeh</surname><given-names>KH</given-names></name><name><surname>Cheng</surname><given-names>AL</given-names></name><name><surname>Lin</surname><given-names>MT</given-names></name><name><surname>Hong</surname><given-names>RL</given-names></name><name><surname>Hsu</surname><given-names>CH</given-names></name><name><surname>Lin</surname><given-names>JF</given-names></name><name><surname>Chang</surname><given-names>KJ</given-names></name><name><surname>Lee</surname><given-names>PH</given-names></name><name><surname>Chen</surname><given-names>YC</given-names></name></person-group><article-title>A phase II study of weekly 24-hour infusion of high-dose 5-fluorouracil and leucovorin (HDFL) in the treatment of recurrent or metastatic colorectal cancers</article-title><source>Anticancer Res</source><year>1997</year><volume>17</volume><fpage>3867</fpage><lpage>3871</lpage><!--PubMed citation query: 'Anticancer Res||17|3867||bib51|'--><pub-id pub-id-type="pmid">9427794</pub-id></citation></ref><ref id="bib52"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Yeh</surname><given-names>KH</given-names></name><name><surname>Yeh</surname><given-names>SH</given-names></name><name><surname>Chang</surname><given-names>YS</given-names></name><name><surname>Cheng</surname></name></person-group><article-title>Minimal toxicity to myeloid progenitor cells of weekly 24-hr infusion of high-dose 5-fluorouracil: direct evidence from colony forming unit-granulocyte and monocyte (CFU-GM) clonogenic assay</article-title><source>Pharmacol Toxicol</source><year>2000a</year><volume>86</volume><fpage>122</fpage><lpage>124</lpage><!--PubMed citation query: 'Pharmacol Toxicol||86|122||bib52|'--><pub-id pub-id-type="pmid">10752669</pub-id></citation></ref><ref id="bib53"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Yeh</surname><given-names>KH</given-names></name><name><surname>Yeh</surname><given-names>SH</given-names></name><name><surname>Hsu</surname><given-names>CH</given-names></name><name><surname>Wang</surname><given-names>TM</given-names></name><name><surname>Ma</surname><given-names>IF</given-names></name><name><surname>Cheng</surname><given-names>AL</given-names></name></person-group><article-title>Prolonged and enhanced suppression of thymidylate synthase by weekly 24-h infusion of high-dose 5-fluorouracil</article-title><source>Br J Cancer</source><year>2000b</year><volume>83</volume><fpage>1510</fpage><lpage>1515</lpage><!--PubMed citation query: 'Br J Cancer||83|1510||bib53|'--><pub-id pub-id-type="pmid">11076661</pub-id></citation></ref><ref id="bib54"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Zaniboni</surname><given-names>A</given-names></name><name><surname>Barni</surname><given-names>S</given-names></name><name><surname>Labianca</surname><given-names>R</given-names></name><name><surname>Marini</surname><given-names>G</given-names></name><name><surname>Pancera</surname><given-names>G</given-names></name><name><surname>Giaccon</surname><given-names>G</given-names></name><name><surname>Piazza</surname><given-names>E</given-names></name><name><surname>Signaroldi</surname><given-names>A</given-names></name><name><surname>Legnani</surname><given-names>W</given-names></name><name><surname>Luporini</surname><given-names>G</given-names></name></person-group><article-title>Epirubicin, cisplatin, and continuous infusion 5-fluorouracil is an active and safe regimen for patients with advanced gastric cancer. An Italian Group for the Study of Digestive Tract Cancer (GISCAD) report</article-title><source>Cancer</source><year>1995</year><volume>76</volume><fpage>1694</fpage><lpage>1699</lpage><!--PubMed citation query: 'Cancer||76|1694||bib54|'--><pub-id pub-id-type="pmid">8625036</pub-id></citation></ref></ref-list></back></article>


